Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of albumin-bound paclitaxel + gemcitabine versus carboplatin + gemcitabine in cisplatin-ineligible advanced or metastatic urothelial carcinoma
ChiCTR1900022615Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, gemcitabine and carboplatin in transitional cell carcinoma (TCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Feb 2019; status: recruiting.
02
Drugs
paclitaxelgemcitabinecarboplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR1900022615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022615.